Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial

M. R. Rigby, L. A. DiMeglio, M. S. Rendell, E. I. Felner, J. M. Dostou, S. E. Gitelman, C. M. Patel, K. J. Griffin, E. Tsalikian, P. A. Gottlieb, C. J. Greenbaum, N. A. Sherry, W. V. Moore, R. Monzavi, S. M. Willi, P. Raskin, A. Moran, W. E. Russell, A. Pinckney, L. Keyes-ElsteinM. Howell, S. Aggarwal, N. Lim, D. Phippard, G. T. Nepom, J. McNamara, M. R. Ehlers

Research output: Contribution to journalComment/debate

Fingerprint Dive into the research topics of 'Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial'. Together they form a unique fingerprint.